Via Tech Md's Cervical Stabilization Device

Answer: ViaTechMD's Cervical Stabilization Device's phone number is +14*********

Answer: ViaTechMD's Cervical Stabilization Device's official website is https://viatechmd.org

Answer: ViaTechMD's Cervical Stabilization Device's revenue is Under $1 Million

Answer: ViaTechMD's Cervical Stabilization Device has 1-10 employees

Answer: ViaTechMD's Cervical Stabilization Device is in Medical Devices

Answer: ViaTechMD's Cervical Stabilization Device contact info: Phone number: +14********* Website: https://viatechmd.org

Answer: ViaTechMD has invented and developed the first and only device-based treatment specifically designed to treat a wide range of conditions known to contribute to preterm birth (PTB). PTB is a growing global healthcare crisis and is the leading cause of infant death and morbidity within the first months of life. Approximately 10% of all global live births are preterm (before 37 weeks of gestation). Annually, an estimated 15 million babies are born preterm -- 3,000 per day do not survive. PTBs annual socioeconomic and medical complication costs are estimated to exceed $52 billion. PTB is also recognized as one of the most significant contributing factors to lifelong crippling diseases including autism, cerebral palsy, blindness, deafness, various respiratory ailments and cognitive and learning disabilities. The Companys Cervical Stabilization Device (CSD), promises a highly accessible, cost-effective, non-invasive, and medication-free, treatment in prevention of PTB. CSD functions to extend gestation in support of a successful and natural birth, addressing various conditions known to contribute to PTB, including: cervical incompetence, organ and tissue compromise, multiple fetus pregnancies and late-in-life pregnancies. The Companys first series of very successful CSD human fitment studies was completed in January of 2017. The Generation 6.1 CSD design was then finalized and will undergo human fitment studies beginning in Q-3 2021 ahead of an Outside United States (OUS) single-arm gravid patient trial scheduled to begin in Q-3 2021. The CSD is protected by a growing global patent portfolio, currently consisting of 32 Utility payments n 18 countries.

Answer:

• Twitter
• LinkedIn